#HOPE4LIVER
HistoSonics Announces First Patient Treated in US Clinical Study of Novel Sonic Beam Therapy for Liver Tumors
HistoSonics announced today the treatment of the first patient in the #HOPE4LIVER US Study. The ...
#HOPE4LIVER
HistoSonics Receives Approval To Begin European #HOPE4LIVER Clinical Study
HistoSonics announced today that it has received approval to initiate the company’s second Europe...
News
HistoSonics Announces $15M Debt Facility Agreement with Signature Bank
HistoSonics Announces $15M Debt Facility Agreement with Signature Bank. HistoSonics is proud to ...
News
HistoSonics Selected as 2020 Red Herring Top 100 North America Winner
HistoSonics was chosen as a 2020 Red Herring Top 100 North America Winner. “What has excited me m...
#HOPE4LIVER
HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study
HistoSonics announced today that it has received approval of an Investigational Device Exemption ...
News
HistoSonics Announces $40 Million Financing
HistoSonics announced today that it has closed $40 million in an oversubscribed Series C-1 financ...
News
HistoSonics Appoints Dr. Joe Amaral to Vice President of Medical Affairs
HistoSonics announced today the appointment of Joe Amaral, MD, to the newly created position of V...
News
HistoSonics Wins Top Honors in The Observer’s List of Top Healthcare Start-ups
HistoSonics was named by The Observer as the one of the nation's most influential healthcare comp...
News
HistoSonics Wins Prestigious Frost & Sullivan Award
Frost & Sullivan announced that it has awarded HistoSonics its prestigious 2019 North America...
News
HistoSonics Closes $54 Million Series C Financing
HistoSonics announced today that it has closed a $54 million Series C financing. The round was l...